{
     "PMID": "25666032",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20160101",
     "LR": "20170220",
     "IS": "1873-7064 (Electronic) 0028-3908 (Linking)",
     "VI": "93",
     "DP": "2015 Jun",
     "TI": "The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice.",
     "PG": "134-45",
     "LID": "10.1016/j.neuropharm.2015.01.027 [doi] S0028-3908(15)00043-X [pii]",
     "AB": "Alzheimer's disease (AD) is the most common senile dementia in the world. Although important progress has been made in understanding the pathogenesis of AD, current therapeutic approaches provide only modest symptomatic relief. In this study, we evaluated the neuroprotective effect of quercetin (25 mg/kg) administration via i.p. injection every 48 h for 3 months on aged (21-24 months old) triple transgenic AD model (3xTg-AD) mice. Our data show that quercetin decreases extracellular beta-amyloidosis, tauopathy, astrogliosis and microgliosis in the hippocampus and the amygdala. These results were supported by a significant reduction in the paired helical filament (PHF), beta-amyloid (betaA) 1-40 and betaA 1-42 levels and a decrease in BACE1-mediated cleavage of APP (into CTFbeta). Additionally, quercetin induced improved performance on learning and spatial memory tasks and greater risk assessment behavior based on the elevated plus maze test. Together, these findings suggest that quercetin reverses histological hallmarks of AD and protects cognitive and emotional function in aged 3xTg-AD mice.",
     "CI": [
          "Copyright (c) 2015 Elsevier Ltd. All rights reserved."
     ],
     "FAU": [
          "Sabogal-Guaqueta, Angelica Maria",
          "Munoz-Manco, Juan Ignacio",
          "Ramirez-Pineda, Jose R",
          "Lamprea-Rodriguez, Marisol",
          "Osorio, Edison",
          "Cardona-Gomez, Gloria Patricia"
     ],
     "AU": [
          "Sabogal-Guaqueta AM",
          "Munoz-Manco JI",
          "Ramirez-Pineda JR",
          "Lamprea-Rodriguez M",
          "Osorio E",
          "Cardona-Gomez GP"
     ],
     "AD": "Neuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area, Faculty of Medicine, University of Antioquia, Calle 70 No. 52-21, Medellin, Colombia. Neuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area, Faculty of Medicine, University of Antioquia, Calle 70 No. 52-21, Medellin, Colombia. Grupo de Investigacion en Sustancias Bioactivas, Facultad de Quimica Farmaceutica, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellin, Colombia; Group of Immunomodulation, Faculty of Medicine, University of Antioquia, Calle 70 No. 52-21, Medellin, Colombia. Neuroscience Laboratory, Psychology Department, Universidad Nacional de Colombia, Bogota, Colombia. Grupo de Investigacion en Sustancias Bioactivas, Facultad de Quimica Farmaceutica, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellin, Colombia. Neuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area, Faculty of Medicine, University of Antioquia, Calle 70 No. 52-21, Medellin, Colombia. Electronic address: patricia.cardonag@udea.edu.co.",
     "LA": [
          "eng"
     ],
     "GR": [
          "R01 AG029802/AG/NIA NIH HHS/United States",
          "1 R01 AG029802-01/AG/NIA NIH HHS/United States"
     ],
     "PT": [
          "Journal Article",
          "Research Support, N.I.H., Extramural",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20150207",
     "PL": "England",
     "TA": "Neuropharmacology",
     "JT": "Neuropharmacology",
     "JID": "0236217",
     "RN": [
          "0 (Amyloid beta-Peptides)",
          "0 (Amyloid beta-Protein Precursor)",
          "0 (Antioxidants)",
          "0 (Nerve Tissue Proteins)",
          "0 (Presenilin-1)",
          "0 (tau Proteins)",
          "9IKM0I5T1E (Quercetin)"
     ],
     "SB": "IM",
     "MH": [
          "Aging",
          "Alzheimer Disease/complications/*drug therapy/genetics/*pathology",
          "Amyloid beta-Peptides/metabolism",
          "Amyloid beta-Protein Precursor/genetics",
          "Animals",
          "Antioxidants/*therapeutic use",
          "Brain/drug effects/metabolism/*pathology",
          "Cognition Disorders/etiology/*prevention & control",
          "Disease Models, Animal",
          "Drug Administration Schedule",
          "Gliosis/etiology/prevention & control",
          "Maze Learning/drug effects",
          "Mice",
          "Mice, Transgenic",
          "Mood Disorders/etiology/*prevention & control",
          "Nerve Tissue Proteins/metabolism",
          "Neuroglia/pathology",
          "Presenilin-1/genetics",
          "Quercetin/*therapeutic use",
          "Reaction Time/drug effects/genetics",
          "tau Proteins/genetics"
     ],
     "PMC": "PMC4387064",
     "MID": [
          "NIHMS665036"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Alzheimer's disease",
          "Cognitive function",
          "Neuroprotection",
          "Quercetin",
          "Tauopathy",
          "beta-amyloidosis"
     ],
     "EDAT": "2015/02/11 06:00",
     "MHDA": "2016/01/02 06:00",
     "CRDT": [
          "2015/02/11 06:00"
     ],
     "PHST": [
          "2014/09/22 00:00 [received]",
          "2015/01/21 00:00 [revised]",
          "2015/01/26 00:00 [accepted]",
          "2015/02/11 06:00 [entrez]",
          "2015/02/11 06:00 [pubmed]",
          "2016/01/02 06:00 [medline]"
     ],
     "AID": [
          "S0028-3908(15)00043-X [pii]",
          "10.1016/j.neuropharm.2015.01.027 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuropharmacology. 2015 Jun;93:134-45. doi: 10.1016/j.neuropharm.2015.01.027. Epub 2015 Feb 7.",
     "term": "hippocampus"
}